Supreme Court E-Library
Information At Your Fingertips


  View printer friendly version

(NAR) VOL. 1 NO.2 / APRIL - JUNE 1990

[ DDB BOARD REGULATION NO. 5-B, s. 1983, October 19, 1983 ]

AMENDMENT OF BOARD REGULATION NO. 3, SERIES OF 1981 TO ALLOW CERTAIN PREPARATIONS WITH PROPOXYPHENE NAPSYLATE TO BE PRESCRIBED THROUGH ORDINARY PRESCRIPTION WITHOUT NEED OF INDICATING THEREIN THE S-2 LICENSE NUMBER OF THE PRESCRIBING PHYSICIAN



Pursuant to the powers vested in it under Section 36 (a) of RA 6425 as amended, and following its decision arrived at in a meeting of October 19, 1983, the Dangerous Drugs Board hereby amends Board Regulation No. 3, series of 1981 such that the second paragraph thereof shall read as follows:

"As exempt preparations these combination products shall be prescribed through the ordinary prescription form which need not indicate therein the S-2 license number of the prescribing physician but which shall contain the name and address of the physician and the patient.  These products shall however continue to be subject to the following requirements:

1.            Registration (with the Bureau of Food and Drug)

2.            Records-keeping (in the ordinary prescription book)

3.            Inspection of wholesale and retail trade — All products falling within the classification herein made are subject to inspection by the authorized officers of the Bureau of Food Drug and the Dangerous Drugs Board insofar as regards the purpose and functions of each of the said officers.

4.            Limitations of imports and exports.

5.            Reports to be furnished by the importers/manufacturers."

This amendment shall take effect upon completion of its publication in a newspaper of general circulation once a week for two consecutive weeks.

Adopted: 19 Oct. 1983

(SGD.) J.C. AZURIN
(Minister of Health)
Chairman

© Supreme Court E-Library 2019
This website was designed and developed, and is maintained, by the E-Library Technical Staff in collaboration with the Management Information Systems Office.